Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.79)
# 1,620
Out of 4,829 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.20 | +1,733.33% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $5.08 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.04 | +376.19% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $17.38 | +463.87% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $19.70 | +534.52% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.87 | +862.57% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.22 | +755.86% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.62 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $8.18 | +7,234.96% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $186.93 | -57.65% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $51.63 | +200.21% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.36 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.70 | +575.68% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.25 | +100,531.41% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $1.49 | +120,705.37% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $41.72 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.13 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.99 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.25 | +20,110.19% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.84 | +23,365.00% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $5.98 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $18.63 | +1,107.73% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.89 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.46 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.20
Upside: +1,733.33%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.08
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.04
Upside: +376.19%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $17.38
Upside: +463.87%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $19.70
Upside: +534.52%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.87
Upside: +862.57%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.22
Upside: +755.86%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.62
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $8.18
Upside: +7,234.96%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $186.93
Upside: -57.65%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $51.63
Upside: +200.21%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.36
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.70
Upside: +575.68%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.25
Upside: +100,531.41%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $1.49
Upside: +120,705.37%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $41.72
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.13
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $6.99
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.25
Upside: +20,110.19%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.84
Upside: +23,365.00%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $5.98
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $18.63
Upside: +1,107.73%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $3.89
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.46
Upside: -